Results in PRIME and PRIME 2
≥4-POINT IMPROVEMENT IN WI-NRS AT WEEK 24
(primary endpoint)1-3,a
- A nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo)3
Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.
aBaseline WI-NRS scores: 8.6 (SD, 0.9) for DUPIXENT, 8.3 (SD, 1.1) for placebo.2
PRIME2 (18+ YEARS)
- A nominal difference in itch improvement was observed at Week 11 (33% with DUPIXENT vs 17% with placebo), with a significantly greater proportion of DUPIXENT patients achieving a meaningful itch response at Week 12 (37% with DUPIXENT vs 22% with placebo; P=0.022, primary endpoint)1-3
- At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo (P<0.001, secondary endpoint)1,2
Definitive conclusions cannot be made for results at timepoints other than Weeks 12 and 24 in PRIME2. Data were not multiplicity controlled.
PRIME AND PRIME2 POOLED ANALYSIS
Itch improvement observed after first dose (as measured at Week 2)3,4
- 7.8% of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 2 vs 1.9% with placebo
- 59% of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 24 vs 19% with placebo
Definitive conclusions cannot be made as this was a post hoc analysis in which data were not multiplicity controlled and P values were nominal.
DUPIXENT showed consistent itch improvement regardless of patients’ atopic background5
≥4-POINT IMPROVEMENT IN WI-NRS AT WEEK 24 REGARDLESS OF
PATIENTS’ HISTORY OF ATOPY5
Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.
In the PRIME trials, patients were stratified by their history of atopy.
Watch healthcare providers discuss itch improvement with DUPIXENT
Q2W, once every 2 weeks; SD, standard deviation; WI-NRS, Worst Itch numerical rating scale.